Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 6/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558328 | 1.00 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL14767811 | 0.92 | PLA2G2A (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL7584842 | 0.84 | MAPK1 (0.60) | KMT2AMAPK1 | |
| SCHEMBL14803813 | 0.81 | CHRM2 (0.55) | KMT2A | |
| SCHEMBL14803815 | 0.81 | CHRM2 (0.55) | KMT2A | |
| SCHEMBL15267482 | 0.81 | MAOB (0.48) | — | |
| SCHEMBL14803822 | 0.81 | CHRM2 (0.55) | KMT2A | |
| SCHEMBL14803817 | 0.81 | CHRM2 (0.55) | KMT2A | |
| SCHEMBL10198316 | 0.80 | ALDH1A1 (0.42) | KMT2A | |
| SCHEMBL10107970 | 0.80 | ALDH1A1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| EP-2567693-A1 | Lipid encapsulated interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2013-03-13 | — | — | EP | disclosed |
| EP-1664316-B1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS INC (CA) | 2012-08-29 | — | — | EP | disclosed |
| EP-1664316-B1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS INC (CA) | 2012-08-29 | — | — | EP | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-10-26 | — | — | US | disclosed |
| WO-2006074546-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-07-20 | — | — | WO | disclosed |
| EP-1664316-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | Protiva Biotherapeutics Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| EP-1648519-A2 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-08-11 | — | — | US | disclosed |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005026372-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005007196-A2 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064595-A1 | Lipid encapsulated interfering RNA | ABHD16A, LDLR, RNASE1 | PLA2G2A 78/4885PLA2G10 485/4885PLA2G1B 277/4885 |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | LIPA, PNLIP, PLTP | PLA2G2A 150/4885PLA2G10 300/4885PLA2G1B 316/4885 |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | PLA2G2A 78/4885PLA2G10 485/4885PLA2G1B 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.